Medpace Holdings Inc vs 3M Company — how do they compare? Medpace Holdings Inc trades at $599.34 (market cap $16.90B), while 3M Company trades at $181.33 (market cap $94.44B). The key difference: 3M Company is far larger — about 5.6× Medpace Holdings Inc's market cap, and 3M Company pays a 1.7% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | MMM | |
|---|---|---|
Market Cap | $16.90B | $94.44B |
Sector | Technology | Industrials |
52-Week High | $620.59 | $183.13 |
52-Week Low | $393.42 | $141.10 |
Enterprise Value | $16.52B | $103.67B |
Dividend Yield | — | 1.7% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
MMM trades at $182.04, showing modest daily weakness but maintaining a bullish technical trend with strong support near $181. Recent Q2 2026 earnings beat expectations with EPS of $2.40, driven by 5.4% organic growth and margin expansion, leading to raised full-year guidance. The stock's valuation remains elevated with a P/E of 32.53, while analyst sentiment is mixed with a near-even split between buy and hold ratings.
The outlook is cautiously optimistic, supported by operational improvements and innovation in high-growth verticals like Safety & Industrial. Key risks include litigation liabilities and macroeconomic pressures. Upside potential exists if execution continues to surpass expectations, but current prices may already reflect near-term gains.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →